Apheresis is a process used to separate donated blood's red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma in order to treat various ailments. It aids in the treatment of sickle cell disease, a condition where the body's red blood cells (RBCs) cannot transport oxygen because of their irregular form. Additionally, it is used to eliminate aberrant white blood cells (WBCs), which cause blood to thicken and impair organ function. Apheresis is also commonly utilized in blood banks, hospitals, and ambulatory clinics worldwide because it helps cure blood malignancies and illnesses like myasthenia gravis and thrombotic thrombocytopenic purpura (TTP).

The market for apheresis in 2021 was worth USD 1.79 billion, and by 2030 it will be worth USD 3.87 billion, growing at a 7.78% CAGR during the forecast period. 

The market is growing as a result of rising rates of blood cancer among people. Furthermore, the market is rising due to the increasing use of apheresis procedures in the treatment of illnesses like hematological, cardiology, and autoimmune conditions, as well as the rising demand for plasma from the biopharmaceuticals sector.

Market Dynamics

Drivers

The rising prevalence of diseases, an increase in the demand for blood components and the safety that goes along with them, technological advancements in the creation of new apheresis techniques, and an increase in reimbursement policies and funding for apheresis procedures are the driving forces behind the growth of the apheresis market. In June 2022, NHS England selected the Spectra Optia Apheresis System's automated red blood cell exchange (RBCX) treatment to treat sickle cell disease as part of the NHS MedTech Funding Mandate (MTFM) in the United Kingdom. It will lead to greater adoption of Spectra Optia in hospitals across England. 

Restraints

The market growth is hampered by the lack of skilled professionals, growing blood contamination, and the high cost of the apheresis process. 

Opportunity 

· An increase in demand for plasma-derived medicines presents significant prospects for market expansion.

· The rising rate of chronic diseases, the rise in surgical procedures, and the rise in accidents and injuries are all driving the market's expansion.

Market Segmentation

By product

On the basis of product, the market is segmented into software, apheresis devices, and disposable & reagents. 

The disposable apheresis kits segment led the entire market due to advancements in the production of blood bags, tubing, and disposable kits. In addition, the developed countries' increasing demand for automated component separation procedures is fueling market expansion.

 On the other hand, the device segment will grow at the quickest rate due to various factors, including the development of healthcare infrastructure, rising demand for automated blood component separators, and an increase in the number of blood donors. Furthermore, the market growth is driven by the introduction of numerous sophisticated and advanced apheresis equipment and rising demand in developing countries.

By Application 

In 2022, the plasmapheresis segment was the largest market, with a revenue share of 53.3%. Patients with compromised immune systems get plasma-based drugs to increase their resistance to infection and disease. The market will expand as the prevalence of blood-related disorders increases and the demand for medicines generated from plasma rises.

By End-User

The blood collection centers and blood component providers held a revenue share of nearly 67.5%. It is due to an increase in the number of blood component testing instruments, an increase in the number of blood centers, and increasing public knowledge of blood collection facilities.

By Technology

In 2022, the centrifugation segment was the biggest market, with a share of 57%) As a result of its increased usage rates, centrifugation produces outcomes that are simpler, quicker, and more accurate than membrane filtering. Additionally, the segment will grow due to the rising demand for automated apheresis systems. To increase product efficiency, businesses are developing technologically sophisticated and automated systems.

Regional Analysis 

North America is the biggest regional market for apheresis due to the rising incidence of blood-related conditions such as metabolic diseases, kidney diseases, and neurological disorders. Furthermore, the rising demand for blood components is another element boosting the expansion of the regional market. The American National Red Cross estimates that 6.8 million people give blood annually. As a result, increased donor camps and an increase in blood transfusions are boosting the US market.

Due to the rising number of blood illnesses requiring platelet and plasma transfusion in developing nations like China and India, the Asia-Pacific market will expand rapidly. The Asia Pacific region is also flourishing due to the expansion of the healthcare infrastructure and the increase in the number of healthcare professionals.

Key Players

· Cerus Corporation

· Terumo BCT

· Asahi Kasei Medical 

· Kawasumi Laboratories 

· Kaneka Corporation

· Fresenius Kabi

· Haemonetics Corporation

· Nikkiso

· B. Braun Melsungen AG

· HemaCare Corporation

The market for apheresis in 2021 was worth USD 1.79 billion, and by 2030 it will be worth USD 3.87 billion, growing at a 7.78% CAGR during the forecast period. The apheresis market is stimulated by the rising rate of chronic disorder, the rise in source plasma demand from biopharmaceutical companies, the rise in demand for blood components & the rise in concerns about the safety of blood, and the favorable reimbursement for apheresis procedures.

Related Reports:

Surgical Sutures Market Report - The global surgical sutures market will witness a robust CAGR of 6.23%, valued at $4.04 billion in 2021, expected to appreciate and reach $6.97 billion by 2030, confirms Strategic Market Research.